OrganOx, an Oxford, UK-based commercial stage organ technology company, raised an undisclosed amount in funding.
Backers included Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC.
The company intends to use the funds to expand operations and its development efforts.
Led by Oern R. Stuge, MD, MBA, Executive Chairman, OrganOx is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The OrganOx metra is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia.
It has been used in over 5,000 liver transplants to date to keep donor livers in a metabolically active state outside the body enabling longer preservation times and functional assessment of the organ prior to transplant.
In conjuction with the first closing of its private placement on February 24, 2025, the company raised $160M in primary and secondary equity financing to accelerate growth opportunities for its metra platform technology in the large and high growth organ technology global market.
FinSMEs
14/05/2025